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Serum squamous cell carcinoma antigen as an
early indicator of response during therapy
of cervical cancer
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John D Pfeifer2,4,5, Julie K Schwarz1,2, Weijun Liu1, Shuai Chen1, David Mutch2,5, Xiaowei Wang1,2,
Matthew A Powell2,5, Barry A Siegel2,6, Farrokh Dehdashti2,6, Gary A Silverman3 and Perry W Grigsby1,2,5,6
1
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Washington University School of Medicine, St Louis, MO 63110, USA and 6Division of Nuclear Medicine, Edward Mallinckrodt
Institute of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA
Background: Pretreatment serum squamous cell carcinoma antigen (SCCA) is a prognostic biomarker in women with cervical
cancer. SCCA has not been evaluated as an early indicator of response to chemoradiation therapy (CRT). The molecular role of the
two SCCA isoforms, SCCA1 (SERPINB3) and SCCA2 (SERPINB4), in cervical cancer is unknown. We hypothesised that changes in
serum SCCA during definitive CRT predicts treatment response, and that SCCA1 mediates radiation resistance.
Methods: Patients treated with definitive CRT for cervical squamous carcinoma with serum SCCA measured were included. SCCA
immunohistochemistry was performed on tumour biopsies. Post-treatment FDG-PET/CT, recurrence, and overall survival were
recorded. Radiation response of cervical tumour cell lines after SCCA1 expression or CRISPR/Cas9 knockout was evaluated by
clonogenic survival assay.
Results: Persistently elevated serum SCCA during definitive CRT was an independent predictor of positive post-therapy FDGPET/CT (P ¼ 0.043), recurrence (P ¼ 0.0046) and death (P ¼ 0.015). An SCCA1-expressing vector increased radioresistance, while
SCCA knock out increased radiosensitivity of cervical tumour cell lines in vitro.
Conclusions: Early response assessment with serum SCCA is a powerful prognostic tool. These findings suggest that escalation of
therapy in patients with elevated or sustained serum SCCA and molecular targeting of SCCA1 should be considered.

The standard treatment for locally advanced cervical cancer is
chemoradiation therapy (CRT). Patients with advanced disease and
lymph node metastases are at risk for recurrence and dying from
cervical cancer (Varia et al, 1998; Rose, 2003; Eifel et al, 2004; Kidd
et al, 2010b). Prognostic biomarkers derived from positron
emission tomography/computed tomography (PET/CT) with

2-[18F]fluoro-2-deoxy-d-glucose (FDG) include high tumour
FDG uptake, large metabolic tumour volumes, and lymph node
involvement at diagnosis (Grigsby et al, 2001; Xue et al, 2006; Kidd
et al, 2007, 2010a). FDG-PET/CT metabolic response assessed
three months after treatment is associated with outcomes (Schwarz
et al, 2007), but a proportion of patients with complete metabolic
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response will still experience recurrence. Moreover, this assessment
does not provide the opportunity to modify upfront therapy. FDGPET/CT also remains a limited resource in locations where cervical
cancer is most prevalent (Horton and Gauvreau, 2015). Prognostic
tools realisable in limited-resource geographic areas could improve
global outcomes for cervical cancer.
We have demonstrated that high pretreatment total serum
squamous cell carcinoma antigen (hereafter referred to as just
SCCA) is associated with recurrence, corroborating prior reports
(Kato and Torigoe, 1977; Crombach et al, 1989; Hsieh et al, 1989;
Bolli et al, 1994; Lin et al, 2000; Micke et al, 2005; Olsen et al,
2011). Similarly, failure of serum SCCA to normalise at the
completion of CRT is a poor prognosis indicator (Ohara et al,
2002; Micke et al, 2005; Olsen et al, 2011). Chen et al (2017)
demonstrated that tumour levels of SCCA protein correlate with
response to neoadjuvant chemotherapy in patients undergoing
surgery for cervical cancer. It is not currently known whether
changes in serum SCCA during CRT indicate response to
radiation. The relationship between serum and protein levels of
SCCA within primary tumours has not been thoroughly reported.
Moreover, evidence exists that SCCA in the serum contains two
isoforms, SCCA1 (SERPINB3) and SCCA2 (SERPINB4). Both are
members of the serine protease inhibitor (serpin) superfamily, with
SCCA1 possibly playing a molecular role in resistance to common
anti-cancer therapies (Suminami et al, 2000; Murakami et al, 2001;
Hsu et al, 2009). A homologue of SCCA1 functions as a prosurvival factor in C. elegans by neutralising endogenous lysosomal
proteases released upon cell stress (Luke et al, 2007). The role of
SCCA1 in mediating tumour response to radiation is unknown.
We evaluated serum SCCA as a part of routine management of
patients with cervical cancer treated with CRT at the time of
diagnosis and weekly during treatment. Here we evaluate changes
in serum SCCA levels as they relate to patient features, clinical
outcomes including recurrence and overall survival, and FDG-PET
results. In addition, we compared intracellular SCCA protein in
pretreatment tumour specimens to circulating SCCA levels from
corresponding serum samples. We used cervical tumour cell lines
to directly test the role of SCCA1 in cervical tumour cell response
to radiation.
MATERIALS AND METHODS

Patients and treatment. Prior approval from the Institutional
Review Board with waiver of consent was obtained before
reviewing medical records and existing specimens. Biopsy proven
squamous cell carcinoma of the cervix and completed definitive
CRT were inclusion criteria. The approach for definitive CRT at
our institution has been previously described (Dyk et al, 2014).
Briefly, patients were prescribed 50.4 Gray (Gy) external beam
radiation therapy (EBRT) in 1.8 Gy fractions four days per week to
the pelvis; para-aortic lymph node regions were included if
involved on pre-treatment FDG-PET. Dose reduction of 10% in
EBRT dose (prescribed dose 45 Gy) was employed for elderly
patients or those with very low body mass index (o18.5; Kizer
et al, 2011). Intensity modulated radiation therapy (IMRT) and a
split-pelvis or pseudo-step wedge technique were used with
brachytherapy boost in six once-weekly fractions to a nominal
high-dose rate (HDR) prescription of 6.5 Gy to point A (39 Gy
total). Patients received concurrent weekly cisplatin at a dose of
40 mg m  2.
Serum SCCA. Serum SCCA assay was performed by ARUP
National Reference Laboratory (Salt Lake City, UT, USA), using an
enzyme-linked immunosorbent assay (ELISA; normal range 0.0–
2.2 ng ml  1). Pretreatment serum SCCA was determined up to two
months before the start of CRT and posttreatment within seven
www.bjcancer.com | DOI:10.1038/bjc.2017.390
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days of completing all radiation. On-treatment serum SCCA was
binned into seven-day increments, and patients with at least three
on-treatment serum SCCA levels (to allow a trend) were included
for sub-analyses.
FDG-PET/CT. Pre- and posttreatment FDG-PET/CT was performed per routine clinical care. Standardised uptake value (SUV),
a semiquantitative measure of radiotracer uptake, was used to
calculate FDG uptake within the primary tumour (SUV ¼ tissue
radioactivity concentration (nCi ml  1)/[injected dose (mCi)/
patient weight (g)) (Kidd et al, 2007). The primary tumour
maximum SUV (SUVmax) was determined as the maximum pixel
SUV within a volume of interest (VOI) encompassing the tumour
(Kidd et al, 2007). Metabolic tumour volume was calculated as the
volume of pixels with tumour VOIX40% of the SUVmax. For
posttreatment FDG-PET/CT assessment, complete metabolic
response was defined as resolution of abnormal FDG uptake at
all sites and no new areas of abnormal FDG uptake, partial
response as persistent abnormal uptake at initial sites of disease,
and progressive disease as any new foci of abnormal uptake
(Schwarz et al, 2007).
Outcome assessment. Recurrence was defined as new or progressive disease in any location (within the primary site, regional
lymph nodes or distant metastases) as determined by clinical
examination and/or imaging, with biopsy confirmation whenever
possible (82% of recurrences were pathologically confirmed).
Patient death was determined by review of the medical record,
online obituary review and search of the Social Security Death
Index. Positive post-therapy FDG-PET performed three months
after completion of treatment was used as a separate outcome.
Immunohistochemistry. Formalin-fixed
paraffin-embedded
(FFPE) tumour specimens were marked for areas of tumour on
haematoxylin and eosin stained slides. Triplicate 1.5 mm tumour
cores were placed in a tissue microarray (TMA) using an MTA-1
Manual Tissue Arrayer (Beecher Instruments, Inc., Sun Prairie,
WI, USA), and 6 mm sections were deparaffinised, rehydrated, and
after humidified heat antigen retrieval, stained with anti-SCCA1
and anti-SCCA2 antibodies (1 : 25, Santa Cruz Biotechnology Inc.,
Santa Cruz, California), and ImmunoCruz LSAB per the
manufacturer’s protocol (Santa Cruz Biotechnology, Inc.). Slides
were digitised and analysed using the web-based Aperio eSlide
Manager platform (Leica Biosystems, Buffalo Grove, IL, USA) in a
blinded fashion by a pathologist with expertise in gynaecologic
cancers (JP). Staining intensity and percent positive tumour cells
were combined to an overall score as having absent, low or high
staining. Subcellular localisation of staining was also noted.
Cell culture. All cell lines were obtained from ATCC and grown
in monolayer at 37 1C/5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM) or Iscove’s modified Dulbecco’s medium
(IMDM) supplemented with 10% foetal bovine serum,
0.1 mg ml  1 penicillin, 100 units per ml streptomycin, and
15 mM Hepes.
siRNA-mediated knockdown and generation of transgenic cell
lines. HT3 cells were transfected with 30 nM siRNA (SCCA1 (h)
sc-40950 or scramble siRNA sc-37007, Santa Cruz Biotechnology,
Dallas, TX, USA) with Lipofectamine RNAiMAX (Thermo Fisher
Scientific, Waltham, MA, USA) per manufacturer’s protocol.
Knockdown was evaluated by qRT-PCR (primers in
Supplementary Table 1) and WB after 24 and 48 h respectively.
siRNA treated cells were seeded for radiation 24 h later. Clustered
Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9
mediated knockout of SERPINB3 was achieved using the
LentiCRISPR V2 (Addgene 52961, Addgene, Cambridge, MA,
USA) plasmid with either an empty guide RNA (gRNA) cassette or
gRNA directed to the SERPINB3 sequence inserted as previously
73
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described (Shalem et al, 2014). Briefly, an all-in-one lentiviral
plasmid, LentiCRISPR V2 (Addgene 52961), was engineered to
house the SERPINB3-specific single guide RNA (sgRNA),
50 -CACCGGCCTGTACATCCTCCAGCG-30 , identified using the
publically available tool WU-CRISPR (available at http://crispr.wustl.edu/). 293 T cells were transduced with the plasmid for viral
packaging, and HT3 and SW756 parent cell lines were infected
with lentivirus. Puromycin-selected single cell clones were
established, and knockout confirmed with WB analysis and
genomic sequencing for SERPINB3 and potential off-target loci
(Supplementary Table 1).
Western blot. Cells were lysed with Cell Lysis Buffer (Cell
Signaling Technology, Danvers, MA) supplemented with proteinase/phosphatase inhibitors and PMSF. Equal parts protein
(25–30 mg) and Laemmli sample buffer (Santa Cruz Biotechnology,
Dallas, TX, USA) were boiled at 95 1C for 10 minutes and gel
electrophoresed on 4–20% gradient gels (Mini-Protean TGX, BioRad, Hercules, CA, USA), transferred to PVDF blot using the
Trans-Blot Turbo Transfer system (Bio-Rad, Hercules, CA, USA),
blocked with 5% milk:TBS-Tween and incubated with 1 : 4000 antiSCCA1 antibody (NBP2, Novus International, Saint Louis, MO,
USA) overnight at four degrees Celsius, 1 : 100 000 anti-Actin
(A5441, Santa Cruz Biotechnology, Dallas, TX, USA) or 1 : 2000
anti-GAPDH-HRP conjugated antibody (D16H11, Cell Signaling
Technology, Danvers, MA, USA) for 2 h at room temperature.
Anti-mouse or anti-rabbit HRP-conjugated secondary antibody
was used for detection with ECL chemiluminescent reagent (GE
Healthcare Life Sciences, Pittsburgh, PA, USA), visualised, and
quantified using the Bio-Rad ChemiDoc MP imaging system and
Image Lab software (Bio-Rad, Hercules, CA, USA).
Clonogenic survival assay. Five hundred cells per well were
seeded in six-well plates 24 h prior to treatment with increasing
doses of radiation (2, 4, 6 Gy x 1) at 300 cGy per minute using the
RS-2000 Biological System (Rad Source, Suwanee, GA, USA) and
incubated for 1–3 weeks until control plates formed visible colonies
(X50 cells). Plates were fixed and stained with 0.5% crystal violet,
30% Methanol, 10% Acetic Acid, 60% ddH2O for 30 min, rinsed in
tap water and air dried at room temperature. Surviving fraction
was calculated as the number of colonies/(500  plating efficiency).
Statistical analysis. Differences in survival and recurrence were
tested using Kaplan–Meier analysis and log-rank testing. With
various cut-points for serum SCCA published in the literature, we
were motivated to identify the cut point for serum SCCA and time
to normalisation that most effectively stratified our patient
population for disease recurrence outcome. In order to achieve
this, outcome oriented optimal cut-points for serum SCCA at
diagnosis and time to normalisation of serum SCCA were
identified based on the methodology of Contal and O’Quigley
(Contal and O’Quigley, 1999). This methodology uses log rank test
statistics with adjustments to preserve the type-I error rate. Odds
ratio testing was used to determine an association between positive
posttreatment FDG-PET and SCCA characteristics. Factors that
were univariately significant for recurrence were considered for
multivariate Cox-regression; however, given the known covariance
of serum SCCA variables, separate models were built for each
serum SCCA variable. Statistical significance threshold was
Po0.05. All cell line experiments were performed in triplicate.
Clonogenic cell survival curves were compared using linear
repeated measures analysis.
RESULTS

Patients and outcomes. A total of 140 individual patients were
treated with definitive CRT for cervical squamous carcinoma with
74
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Table 1. Patient characteristics
Age (mean, range)

52 years, 25–83 years

Race
Caucasian
Black
Asian
Hispanic

93
38
6
3

(66.4%)
(27.2%)
(4.3%)
(2.1%)

13
30
2
57
5
30
3

(9.4%)
(21.4%)
(1.4%)
(40.7%)
(3.6%)
(21.4%)
(2.1%)

Stage
IB1
IB2
IIA
IIB
IIIA
IIIB
IVA

Node positive (on FDG-PET)
Pelvic LN
PA LN
Chemotherapy

82 (58.6%)
24 (17.1%)
140 (100%)

Status at last follow-up
NED
AWD
DOD
DICD

86
14
36
4

(61.4%)
(10%)
(25.7%)
(2.9%)

Abbreviations: AWD ¼ alive with disease; DICD ¼ died of intercurrent disease; DOD ¼ died
of disease; LN ¼ lymph node; NED ¼ no evidence of disease; PA LN ¼ para-aortic.

FDG-PET/CT and had assessment of serum SCCA. Supplementary
Figure 1 demonstrates the patients included for each analysis. All
but three patients had serum SCCA measured before CRT. Of 100
patients with elevated serum SCCA (42.2 ng ml  1), all had at
least three (maximum six) on-treatment serum SCCA values and
values at the completion of therapy available. FFPE specimens were
available for 102 patients (73%) in triplicate. Posttreatment FDGPET was obtained on 131 patients (94%) included in the study, and
obtained a median of 13 weeks after completion of therapy.
Cohort characteristics are displayed in Table 1. Pelvic lymph
node involvement was detected by pre-treatment FDG-PET/CT in
58.6% of patients. All patients received concurrent cisplatin-based
chemotherapy. Median time to completion of CRT was 48 days
(range 43–95).
Median follow-up for all patients was 24.7 months, and 28.5
months for living patients. Crude recurrence rate was 36.4% with
19 pelvic only failures, 21 distant failures, and 11 pelvic and distant
failures. Pathologic confirmation of recurrence with biopsy was
obtained for 42 patients (82% of recurrences). At the time of last
follow-up, 86 patients were alive and free of disease (61.4%), 36
patients had died of cervical cancer (25.7%), and four of
intercurrent disease (2.9%).
Serum SCCA. Pretreatment serum SCCA was obtained a median
of 19 days prior to the start of EBRT (range; 3–37 days). Two
patients had initial serum SCCA measured days two and three,
respectively, of radiation therapy and were considered pretreatment values. The optimal cut-point for pretreatment serum SCCA
identified as the most significant threshold for recurrence in our
patient population (see Statistical Methods section) was found to
be 16.1 ng ml  1. Patients with high pretreatment serum SCCA
(X16.1 ng ml  1) had significantly higher risk of positive posttreatment FDG-PET (P ¼ 0.0063), disease recurrence (Po0.0001),
and death (Po0.0001), compared to those with low pretreatment
serum SCCA (o16.1 ng ml  1), Table 2 and Figure 1A and B. In
patients with elevated pre-treatment SCCA (X2.2 ng ml  1) failure
of serum SCCA to normalise (p2.2 ng ml  1) by the completion of
therapy was associated with increased risk of recurrence
www.bjcancer.com | DOI:10.1038/bjc.2017.390
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(P ¼ 0.016), death (P ¼ 0.006), and positive post-therapy FDG-PET
(P ¼ 0.049), Figure 1C and D, and Table 2.
Serum SCCA decreased over the course of CRT, with patients who
experienced recurrence having significantly higher serum SCCA
during the first 2 weeks of CRT (Figure 2A). In patients with elevated
pre-treatment SCCA (X2.2 ng ml  1) failure of SCCA to normalise by
the 27th day of CRT was identified as the optimal time cut-point for
prediction of recurrence and was an early indicator of increased risk
of positive posttreatment FDG-PET (P ¼ 0.043), recurrence
(P ¼ 0.0046), and death (P ¼ 0.015), Table 2 and Figure 2B and C.
Patients whose serum SCCA normalised by the 27th day of CRT and
whose posttreatment FDG-PET was negative had an especially low
risk of recurrence (Figure 2D).
A multivariate model was constructed from factors found to be
associated with recurrence on univariate analysis, including FIGO
stage, lymph node status (positive or negative by FDG-PET/CT),
serum SCCA at diagnosis, serum SCCA normalisation by the
completion of therapy, and time to normalisation of serum SCCA.
Age, use of chemotherapy and other factors were not significant on
univariate analysis and thus excluded from multivariate models.
Table 2. Odds ratio for positive post-therapy FDG-PET and
serum SCCA metrics in patients with pre-treatment serum
SCCAX2.2 ng ml  1
Serum SCCA metric

Odds ratio

95% CI

P Value

4.2

[1.5–11.76]

0.0063

Pretreatment
SCCAX16.1 ng ml  1
SCCA normalised by COT ¼ No

2.95

[1.0003–8.7]

0.049

SCCA normalised by 27
days ¼ No

3.1

[1.039–9.25]

0.043

Abbreviation: COT ¼ completion of therapy.

Modulation of SCCA and effect on radiation sensitivity
in vitro. Evaluation of a panel of cervical tumour cell lines
showed variable levels of endogenous steady state SCCA1 protein
by WB and variable radiation resistance by clonogenic cell survival
assay (Figure 3C). We found that expression of GFP-taggedSCCA1 in SW756 cells, which are relatively radioresistant and have
relatively low levels of endogenous SCCA resulted in increased
clonogenic survival following radiation (Figure 3D). siRNAmediated knockdown of SCCA1 in HT3 cells which are radioresistant and have high SCCA1 protein resulted in decreased
mRNA transcript, 2-fold lower protein levels (Supplementary
Figure 2A), and increased radiation sensitivity compared to
scramble-siRNA (P ¼ 0.002, Supplementary Figure 2B). Because
maximum efficiency of knockdown resulted in only 50% protein

SCCA < 16.1 ng ml–1

100
80

SCCA < 16.1 ng ml–1
SCCA ≥ 16.1 ng ml–1
P < 0.0001

100

SCCA ≥ 16.1 ng ml–1
P < 0.0001

Overall survival (%)

Recurrence-free survival (%)

SCCA immunohistochemistry. We next determined the relationship between serum levels of SCCA and intracellular tumour
protein levels. IHC for SCCA1 and SCCA2 on the pretreatment
tumour TMA was interpretable for 72 tumours. Staining for
SCCA1 and SCCA2 was largely concordant between the samples.
Staining ranged from absent to high (Figure 3A) and was
correlated with pretreatment serum SCCA from the same patient
(P ¼ 0.004, Figure 3B). Tumour size, SUVmax, FIGO Stage, and
lymph node status did not correlate with staining intensity (data
not shown). The pattern of cellular staining (cytoplasmic, nuclear,
perinuclear, or some combination) was variable (Supplementary
Figure 2), and had no obvious relationship to serum SCCA.

B

A

60
40
20

80
60
40
20
0

0
0

Number at risk
< 16.1 112
≥ 16.1 25

10
76
8

20
30
40
Time (months)

50

48
4

9
0

33
2

22
1

60
0
0

0
Number at risk
< 16.1 112
≥ 16.1 25

10

20
30
40
Time (months)

50

60

76
8

48
4

9
0

0
0

33
2

22
1

D

C
Normalised
Not normalised
P = 0.016
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Overall survival (%)
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Given inherent covariance of serum SCCA variables, individual
models were built for each of these variables. Both serum SCCA at
diagnosisX16.1ng/mL and failure of SCCA to normalise by the
completion of therapy remained significant on multivariate
analysis as did positive lymph nodes (Supplementary Table 2).
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0
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0
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7
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0
0

Figure 1. Serum SCCA prognostic value. Kaplan-Meier plot of (A) recurrence-free survival and (B) overall survival in all patients (n ¼ 137) with
serum SCCAX16.1 ng/ml at diagnosis compared to those with serum SCCAo16.1 ng ml  1. Kaplan–Meier plot of (C) recurrence-free survival and
(D) overall survival in patients with pre-treatment serum SCCA 42.2 ng/ml (n ¼ 100) that did or did not normalise (p2.2 ng ml  1) by the
completion of therapy (COT).
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Figure 2. Changes in serum SCCA. (A) Mean serum SCCA values over the course of treatment split by recurrence. The number of individual values
available for each time point are found below the graph. Asterisks indicate time points that were statistically different between recurrence and no
recurrence groups. Kaplan–Meier plot of (B) recurrence-free survival and (C) overall survival of patients with pretreatment SCCA42.2 ng ml  1
(n ¼ 100) and normalised serum SCCA by day 27 of CRT, versus those without. (D) Kaplan–Meier plot of recurrence free survival for patients with
normalised serum SCCA by day 27, versus those without, split by positive or negative posttreatment FDG-PET (values available for 93 patients).

reduction, we used CRISPR-Cas9 with single guide RNA against
SERPINB3, the gene encoding SCCA1, to generate SERPINB3
knock out tumour cell lines. This resulted in loss of SCCA1 protein
by WB (Figure 3E), and demonstrated significantly increased
radiation sensitivity of the SERPINB3 KO lines compared to parent
or control cell lines (Figure 3F and G).

DISCUSSION

Women who experience recurrence of cervical cancer after
definitive CRT have a grim prognosis and salvage therapy is
largely ineffective (Eifel et al, 2006). Pre-treatment FDG-PET is
used to guide nodal radiation treatment volumes; however, this
method currently does not allow further individualisation of initial
therapy based on risk. We sought a mechanism of identifying highrisk patients prior to the completion of CRT therapy, providing a
possible opportunity to tailor initial treatment. SCCA is present in
the serum in undetectable or low levels in the general population27
and elevated in many women with cervical cancer portending
worse overall outcome (Crombach et al, 1989; Hsieh et al, 1989;
Bolli et al, 1994; Lin et al, 2000; Ohara et al, 2002; Micke et al,
2005; Olsen et al, 2011). Here we confirm, in a population of
women with squamous cervical cancer treated with uniform CRT,
that pretreatment serum SCCA provides important prognostic
information. We also demonstrate for the first time to our
knowledge that this non-invasive serum test can serve as an early
marker of response to CRT, of recurrence and of death, providing a
window of opportunity to escalate therapy.
Elevated baseline serum SCCA levels can occur in a small
percentage of women with cervical adenocarcinoma and adenosquamous carcinoma (our data not shown; Rose et al, 1993). To
76

eliminate confounders secondary to histology, the current analysis
was limited to squamous histology. Serum levels were obtained
prospectively; however, not all patients had serum SCCA available
for each week of radiotherapy limiting analysis of on-treatment
SCCA. Similarly, not all patients had FFPE-tumour specimens
available, limiting the current study.
While we showed that pretreatment serum SCCA values correlate
with intra-tumoural SCCA by IHC, this measure represents only a
single timepoint; therefore, we turned to cell line models to better
understand the role of SCCA in tumour cell radiation resistance.
Because the literature supports a possible role for SCCA1 in
preventing stress-induced cell death and not SCCA2, we focused on
SCCA1 for these initial mechanistic experiments. We observed that
endogenous steady state SCCA1 was variable in a panel of cervical
tumour cell lines, not unlike primary cervical tumours. We found
that even a transient 50% decrease in SCCA1 protein levels was
sufficient to increase radiation sensitivity as evidenced by the gold
standard clonogenic survival assay. SERPINB3 knockout significantly
decreased clonogenic survival following radiation treatment of
multiple cervical tumour cell lines. Moreover, transfection of an
SCCA1-expressing vector into SW756 increased relative radiation
resistance. The mechanisms are not certain, but several studies
suggest that SCCA1 may protect tumours from the toxic effects of
lysosomal cysteine proteases released upon exposure to noxious
stimuli (Schick et al, 1998; Luke et al, 2007). Consistent with these
findings, our data provide the first evidence to our knowledge that
SCCA1 is directly involved in radiation resistance, and may explain
its prognostic significance in cervical cancer.
‘The Outback Trial,’ an international randomised trial sponsored by the Australia New Zealand Gynaecological Oncology
Group (ANZGOG), with participation of North American
investigators from the NRG Oncology cooperative group, is
currently testing the efficacy of adjuvant systemic chemotherapy
www.bjcancer.com | DOI:10.1038/bjc.2017.390
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Figure 3. Intracellular SCCA1 protein. (A) Representative SCCA1 immunohistochemistry scoring, (B) box plot of SCCA1 staining score versus serum
SCCA at diagnosis for the same patient, (C) ATCC panel of cervical tumour cell lines subject to Western blot analysis of SCCA1 and GAPDH and
relative clonogenic survival of cervical tumour cell lines following increasing doses of RT delivered in a single fraction. (D) Western blot analysis of
SCCA and GAPDH on whole cell lysates from SW756 cells engineered to express GFP only (G) or SCCA-GFP (S-G) construct and resultant relative
clonogenic survival following increasing doses of single-fraction RT. (E) WB analysis of SCCA comparing CRISPR/Cas-9 control (C) gDNA or SERPINB3directed gDNA (KO) in SW756 and HT3 cells. (F and G) Clonogenic survival of parent (WT), control and KO cell lines following increasing doses of RT.

after definitive CRT to reduce the risk of cervical cancer recurrence
(Small). Eligibility criteria are broad and any benefit may be muted
by the inclusion of women with a lower risk of recurrence.
Employment of serum SCCA in this setting could provide a muchneeded tool to further stratify patients for likelihood of benefiting
from such escalated initial therapy and should be considered in the
design of future trials.
We also identified a group of patients with particularly low risk
of recurrence—those with early serum SCCA normalisation and
negative posttreatment FDG-PET—who are unlikely to benefit
from additional therapy regardless of initial tumour stage.
Serum SCCA measured during post-treatment surveillance may
allow early detection of recurrence with a lead-time of more than a
www.bjcancer.com | DOI:10.1038/bjc.2017.390

year before development of symptoms or radiographic recurrence
(Ohara et al, 2002). We are currently evaluating this possibility for
more successful salvage of cervical cancer recurrence. SCCA,
particularly SCCA1 may also be an important molecular factor
involved in tumour cell resistance to radiation therapy. These data
suggest that therapies targeting SCCA1 might increase radiation
sensitivity and reduce the risk of recurrence. Our group is currently
working to explore this possibility.
Elevated serum SCCA at diagnosis is a well-known but rarely
utilised prognostic tool for women with cervical cancer. We
provide the first evidence that failure of serum SCCA to fall into
the normal range by the fourth week of definitive radiotherapy is
associated with significantly increased risk of recurrence and death.
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This easily obtainable serum biomarker can be used to stratify
patients for risk of recurrence and allow modification of initial
treatment with the goal of improved outcomes.
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